VRTX
Vertex Pharmaceuticals Incorporated Common Stock
$548.03
장중 · Vol 60.3K · 52주 $374.17–$555.69 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $538.33 · Aug 31, 2026
VRTX 가격 추세
종가
$538.33
시가
$535.38
고가
$538.89
저가
$532.23
30초 브리핑
VRTX 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 96%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 24.8배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.3배
거래량은 최근 평균 범위입니다.
2026-11-02
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
VRTX 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue · Boston, MA, United States · 직원 6,400명
시가총액
$138.01B
Trailing P/E
31.5
최근 12개월 이익 기준
Forward P/E
24.8
이익 증가 기대 반영
EPS (TTM)
$17.26
배당 수익률
—
배당성향
0.0%
베타
0.30
시장보다 방어적
ROE
23.5%
P/B
6.81
EV/EBITDA
25.8
52주 범위
$374.17 – $555.69
현재 위치 96%
거래량
1.07M
20일 평균 857.2K · 1.3배
애널리스트 의견
매수 79%
총 29명 · 0m
DITM LEAPS Analysis
VRTX 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX280121C00370000 | 1/21/28 · 1.4Y | $370.00 | $216.50 | 2.1x | 0.8520 | 19.4% | 4.16% | 51.29% | 1 | 57.75 |
재무제표
VRTX 연간 손익·현금흐름·재무상태
매출 성장률
+8.9%
최근 연간 YoY
EPS 성장률
+836.5%
최근 연간 YoY
영업이익률
37.9%
최근 연간
FCF 마진
26.6%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $12.00B+8.9% | $11.02B+11.7% | $9.87B+10.5% | $8.93B |
| 매출총이익 | $10.35B+9.1% | $9.49B+10.3% | $8.61B+9.6% | $7.85B |
| 영업이익 | $4.55B+2051.3% | -$233.40M-106.2% | $3.78B-11.0% | $4.25B |
| 순이익 | $3.95B+838.1% | -$535.60M-114.8% | $3.62B+9.0% | $3.32B |
| 희석 EPS | $15.32+836.5% | $-2.08-115.0% | $13.89+8.3% | $12.82 |
| EBITDA | $4.87B+900.7% | $486.30M-89.4% | $4.61B+3.8% | $4.44B |
| 영업현금흐름 | $3.63B+837.2% | -$492.60M-113.9% | $3.54B-14.3% | $4.13B |
| 잉여현금흐름 | $3.19B+426.6% | -$978.00M-129.8% | $3.28B-16.5% | $3.93B |
| 총자산 | $25.64B+13.8% | $22.53B-0.9% | $22.73B+25.2% | $18.15B |
| 총부채 | $2.03B+16.4% | $1.74B+115.8% | $808.40M-10.1% | $899.70M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
VRTX 실적·배당 일정
매출 하단
$3.33B
EPS 하단
$4.66
매출 상단
$3.46B
실적 발표일
2026-11-02
D-62
EPS 상단
$5.18
매출 컨센서스
$3.39B
EPS 컨센서스
$4.92
뉴스
VRTX 관련 최신 기사
일반1 S&P 500 Stock with Exciting Potential and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
StockStory · Aug 31, 2026
제품·기술Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Zacks · Aug 31, 2026
실적Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Zacks · Aug 26, 2026
제품·기술2 Large-Cap Stocks to Research Further and 1 We Question
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
StockStory · Aug 26, 2026
제품·기술Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide
Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.
Motley Fool · Aug 24, 2026
제품·기술Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Motley Fool · Aug 20, 2026
일반Are Wall Street Analysts Bullish on Vertex Stock?
Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.
Barchart · Aug 20, 2026
일반3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.
StockStory · Aug 18, 2026
제품·기술Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]
Insider Monkey · Aug 14, 2026
실적Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?
Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...
Simply Wall St. · Aug 14, 2026
홀더
VRTX 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
98.2%
기관 보유 (유동주식)
98.4%
내부자 보유
0.2%
기관 수
2,437
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Capital World Investors | 26.12M | $14.22B | 10.3% | 2.9% | Jun 30, 2026 |
| Blackrock Inc. | 24.11M | $13.13B | 9.5% | 0.6% | Jun 30, 2026 |
| Capital Research Global Investors | 19.49M | $10.61B | 7.7% | -7.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 16.58M | $9.03B | 6.5% | 0.4% | Jun 30, 2026 |
| State Street Corporation | 11.87M | $6.46B | 4.7% | 1.2% | Jun 30, 2026 |
| Invesco Ltd. | 8.04M | $4.38B | 3.2% | 1.9% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 6.52M | $3.55B | 2.6% | -7.3% | Jun 30, 2026 |
| Geode Capital Management, LLC | 6.02M | $3.28B | 2.4% | -2.0% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 4.88M | $2.66B | 1.9% | -5.2% | Jun 30, 2026 |
| Capital International Investors | 4.70M | $2.56B | 1.8% | -8.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.